Life Sciences 360

Why Most Healthcare Brands Fail (And How to Fix It)In this episode, Holley Miller, Founder and President of Grey Matter Marketing, reveals why most medtech and life sciences companies fail to connect with their audience—and how to fix that with brand clarity and strategic storytelling.You'll learn how marketing in regulated industries is evolving, why flashy tactics often fall flat, and how brand equity is built through consistency, credibility, and emotional connection. Holley also shares lessons from working with emerging startups and large enterprises, offering a strategy for aligning commercial goals with patient and provider trust.

Solving the “Undruggable” Disease Problem with Goldilocks MoleculesIn this episode, Christian Schafmeister, Founder and President of Third Law Molecular, reveals a new class of therapeutics designed to target what most consider “undruggable” diseases—conditions like Alzheimer's, certain cancers, and rare genetic disorders.Christian explains the science behind spiroligomers—modular, mid-sized molecules that act like molecular LEGOs, offering the perfect balance between small molecules and biologics. Learn how his team created a library of 4.5 billion molecules and what makes these structures uniquely suited to bind difficult protein targets, including disordered proteins and intracellular surfaces.We also talk about the Goldilocks Zone of drug design, how Third Law's chemistry was born out of academic and defense-backed research, and why the future of drug discovery may lie in designing therapeutics that are just right.

Why Startups Fail (Hint: It's Not the Innovation)In this episode, Carlo Odicino, CEO and Founder at One TEAM Partners, shares the real reasons why most early-stage life sciences companies struggle to survive—and it has nothing to do with bad science.Learn the hidden pitfalls of scaling too fast, confusing innovation with execution, and chasing too many priorities at once. Carlo offers practical strategies for building focus, setting boundaries, and creating a people-first culture that actually scales. You'll also learn why execution beats experimentation when commercial success is the goal—and how to stay aligned with investors without over-promising.This conversation is packed with actionable advice for startup leaders, biotech founders, and anyone facing the complexities of early-stage growth.

The Hidden Math Behind Drug Pricing: Why Patients Pay More Than They ShouldIn this episode, Michael Grosberg, VP of Product Management at Model N, breaks down the complex drug pricing ecosystem—revealing how rebates, PBMs, and outdated pricing models shape what patients actually pay.You'll learn how Pharmacy Benefit Managers (PBMs) really operate, why list prices are misleading, and how pricing negotiations impact patient access. Michael also unpacks the mechanics behind patient assistance programs, the role of compounding and independent pharmacies, and how emerging technology can bring transparency and efficiency to a broken system.Whether you're in life sciences, healthcare tech, or just want to understand why your prescription costs what it does—this is a must-listen conversation.

Early Commercialization Strategies That Actually Work (Especially for Startups!) In this episode, John Harlow, Chief Commercial Officer at Melinta Therapeutics, shares real-world strategies for how lean pharma startups can win the commercialization game—without Big Pharma budgets.Discover how small companies can pivot fast, creatively optimize distribution, and make strategic decisions without endless red tape. John breaks down the critical mindset shift from R&D to commercial readiness, how to build high-performing teams in resource-constrained environments, and why smaller organizations often out-execute the giants.We also discuss how to prioritize spend, what leaders should know before leaving Big Pharma, and the overlooked advantages of smaller teams.

Healthcare AI adoption is transforming the way we address risk, confidentiality, and patient care. In this episode, RJ Kedziora, co-founder of Estenda Solutions talks about the practical steps to safely integrate AI in clinical workflows. Learn how to manage data privacy, mitigate algorithmic bias, and keep a human in the loop to prevent misdiagnoses. Discover real-world strategies for using AI ethically, from ambient listening to second-opinion checks, and why it's irresponsible not to harness AI's potential. The discussion also highlights how AI can enhance the roles of healthcare professionals, ultimately improving patient outcomes.

Drug serialization is at the heart of modern pharmaceutical supply chain security. In this episode  Michael Rowe, Senior Director of DSCSA and Serialization Services at TwoLabs, talks about the critical role of drug serialization and DSCSA compliance in safeguarding the pharmaceutical supply chain. Michael explains how unique serial numbers, standardized data, and digital traceability are revolutionizing how drugs are tracked from manufacturer to pharmacy. Discover real-world challenges and innovative solutions that ensure product integrity, reduce counterfeiting, and enhance operational efficiency in the pharma industry. Whether you're involved in manufacturing, distribution, or regulatory affairs, learn how embracing drug serialization and DSCSA compliance can transform your operations.

Equitable healthcare is the key to bridging health gaps and creating better patient outcomes. In this episode, Amy West, Principal, Advisory Services at HitLab, share her insights on how technology, digital health, and data can reshape access to care—especially for underserved communities. Learn how addressing social determinants, using remote patient monitoring, and integrating wearables can empower patients and reduce disparities. From real-world examples to actionable insights, Amy shares a vision for a more inclusive and effective healthcare system. Whether you're a clinician, policymaker, or simply curious about the future of medicine, discover how innovative tools and a patient-centric approach can pave the way for true health equity.

Have you ever wondered if AI could help doctors find cancer faster and more accurately? In this episode, we explore OmniScreen, an AI-powered biomarker tool that is revolutionizing cancer diagnostics.Joe Oakley, a pathologist and expert in digital pathology, explains how OmniScreen was trained on 3 million digital slides to detect cancer biomarkers with higher precision and speed. He shares how AI is reducing testing time, preserving tissue samples, and improving early cancer detection.We also tackle the big question: Will AI replace pathologists? Joe breaks down the role of AI in pathology and why it should be seen as a tool to assist rather than replace doctors. Plus, learn how AI is helping hospitals, pharmaceutical companies, and researchers in drug development and clinical trials.

Have you ever wondered why marketing in the life sciences industry is so different from traditional marketing? In this episode, we dive deep into the power of science marketing, the impact of brand storytelling, and how companies can successfully position their products in a competitive market.From publishing content to collaboration with industry, we'll show you how to harness the power of science marketing for success. Why do some breakthrough innovations never reach their full potential, while others become industry leaders?Our guest, Elizabeth Chabe, is the CEO of High Touch Group and a leading expert in scientific marketing. She shares invaluable insights on how companies can build credibility, shorten sales cycles, and effectively communicate complex innovations to investors, researchers, and the public.We also explore:✅ Why scientific breakthroughs fail without proper marketing ✅ The biggest mistakes life sciences companies make ✅ How to pitch complex ideas to experts & decision-makers ✅ The secret behind pharma ads & storytelling in healthcare ✅ How conferences & live demonstrations can transform your brand This episode is packed with expert strategies, real-world examples, and game-changing marketing insights for biotech, medtech, and pharma professionals.⏱️ Chapters:00:00 Introduction02:24 Why Science Marketing is Crucial05:38 How to Tailor Your Message for Experts14:29 The ROI of Marketing – Why It's a Game Changer22:24 The Secret Behind Pharma Ads & Storytelling27:31 A Genius Conference Marketing Strategy32:25 The Future of Science Marketing & Live Engagement35:04 Why Elizabeth Runs a Global Business38:50 A Sneak Peek Into Her Book – The Giants Ladder42:31 Final Thoughts & Takeaways

Have you ever wondered why so many new drugs fail even after years of research and billions in investment? In this episode, we dive deep into the challenges of drug commercialization, the role of AI in pharma, and the biggest mistakes companies make before going to market.Our guest, Dan Cummings, is a leading expert in go-to-market strategy, having worked with top health tech, medtech, and biotech startups. He shares insider insights on why even successful clinical trials don't guarantee a product's success and how companies can improve their chances.We also explore:- The shocking statistics behind drug approvals - Why less than a third of new drugs in 2025 will meet expectations- The #1 mistake pharma companies make before launch - How AI is transforming drug development & commercialization - What makes some drugs cost millions of dollars, while others are much cheaper This episode is packed with industry insights, expert opinions, and bold predictions about the future of pharmaceuticals.Chapters:00:00 Introduction03:54 The Challenges of Drug Commercialization05:35 Market Access & Value-Based Pricing12:00 Predictions for 2025 Drug Approvals13:23 The Role of AI in Pharma16:59 Why Most Drug Launches Miss Expectations18:25 Lessons from Biotech Success Stories23:46 The Future of Pharma & Go-to-Market Strategies29:31 How Companies Can Improve Their Launch Success35:56 Final Thoughts & Takeaways

Have you ever wondered why so many clinical trials fail before reaching the market? In this episode, we dive deep into the hidden challenges of clinical trials with Rob Freishtat, President and Co-Founder of Uncommon Cures and a professor at George Washington University School of Medicine and Health Sciences.Rob shares insider knowledge on why over 55% of clinical trials fail, the high costs of drug development, and how misaligned priorities between researchers, regulators, and sponsors can derail promising treatments. He also reveals how streamlining clinical trials, improving patient recruitment, and leveraging AI and real-world data can help bring life-saving drugs to market faster.If you're curious about the future of medicine, drug approvals, or how rare disease treatments are developed, this is an episode you don't want to miss!Chapters:00:00 Introduction – Why Clinical Trials Matter02:59 The Real Reason Many Clinical Trials Fail08:18 Where the Industry Wastes the Most Money15:28 How Misalignment in Drug Development Happens27:00 The Future of AI in Clinical Trials34:19 How to Fix Broken Clinical Trials41:03 Final Thoughts & Key Takeaways

In this episode of Life Sciences 360, we dive deep into the world of GLP-1 medications with Dr. Jonathan Kaplan. We discuss weight management, how these medications work, their impact beyond weight loss, and the ethical considerations surrounding their use. Dr. Kaplan shares his insights on the healthcare industry's evolving landscape, the economic implications, and why these medications are changing everything from cosmetic surgery to chronic disease management.Chapters:00:00 Introduction  00:02 Dr. Jonathan Kaplan's Background  00:16 Overview of GLP-1 Medications  00:25 The Significance of GLP-1s  00:35 Future FDA Approvals  00:51 Welcome to the Episode  01:12 Meet Dr. Jonathan Kaplan  01:19 Dr. Kaplan's Journey into Weight Management  02:09 Early Days Before the GLP-1 Hype  02:30 Compounding Pharmacy and Medication Shortages  03:17 Success of the Weight Management Program  03:23 YouTube Subscriber Request  04:17 GLP-1 Mechanisms Explained  05:00 How GLP-1s Work in the Body  05:51 Historical Timeline of GLP-1 Medications  06:48 Semaglutide's Evolution  07:23 The Rise of Ozempic and Wegovy  07:43 New Developments in Weight Management  08:54 Accidental Discoveries and Hormones  09:35 Significance of GLP-1 Discoveries  10:02 Medication Approval and Insurance Hurdles  10:43 Patient Expectations vs. Reality  12:09 Misconceptions About Weight Loss  12:51 Other Health Benefits Beyond Weight Loss  14:10 The Complex Psychology of Weight Loss  15:16 Importance of Diet and Exercise  16:10 How to Get Access to These Medications  18:02 Transparent Pricing Model  20:19 Maintenance and Subscription Options  22:04 Challenges with Insurance  23:21 Insurance Pitfalls and Complications  24:42 Speed of Access and Medication Availability  25:41 Ethical Considerations in Prescribing GLP-1s  27:28 Balancing Ethics and Accessibility  29:35 Broader Impact on Public Health and Economics  30:35 Transforming Healthcare Through Weight Management  32:12 Future of GLP-1 Medications  33:58 Changing Consumer Preferences and Food Labels  35:51 Reflections on Dr. Kaplan's Career  37:06 Closing Remarks  39:11 Key Takeaway on Safe Access  41:03 Conclusion and Gratitude  

In this episode of LifeSciences 360, we dive into the fascinating world of cell and gene therapy manufacturing with Carlos Yuraszeck. With over 16 years of experience, Carlos shares his deep insights into the unique challenges, opportunities, and innovations in the field, offering a detailed look into what it takes to bring life-saving therapies to patients. We cover everything from the design of manufacturing facilities to the complexities of quality systems, patient-centric innovations, and the future of allogeneic therapies.If you're interested in the life sciences, cell and gene therapy, or just curious about cutting-edge advancements in medicine, this episode is for you!Chapters:00:00 - Intro  00:02 - Understanding Cell and Gene Therapy Facilities  00:09 - Challenges in Cell Therapy Facility Design  00:26 - Automation in Manufacturing  00:42 - Balancing Quality, Cost, and Time  00:53 - Patient-Centric Manufacturing  01:21 - Guest Introduction: Carlos Yuraszeck  02:06 - Carlos's Journey in Cell and Gene Therapy  03:21 - Unique Factors in Facility Design  04:14 - Making Facilities Operational  05:09 - Subscription Appeal  06:13 - Autologous vs. Allogeneic Cell Therapies Explained  08:13 - Adjusting Processes Based on Patient Variability  09:37 - Stem Cell Derived Therapies  10:39 - Biotech Companies: Autologous or Allogeneic?  12:07 - Strategic Decisions in Facility Design  14:50 - Phase-Appropriate Quality Systems  16:45 - Regulatory Flexibility and Urgency for Patients  18:08 - Change Control in Early vs. Late Phases  19:02 - Batch Records and Operator Judgment  20:27 - Training Focus for Different Phases  22:38 - Balancing Regulatory Requirements and Innovation  24:32 - Risk Assessment Based on Patient Needs  26:18 - The Potential of CAR T Therapies  28:05 - The Allogeneic Space and Future Prospects  31:00 - The Transformative Impact of Cell Therapy  32:22 - Carlos's Career Lessons and Fear of the Unknown  34:45 - Closing Remarks and Subscription Reminder  36:37 - Outro---

In this episode of Life Sciences 360, we dive into the evolution of pharmaceutical and biotech manufacturing with our guest, Scott, a seasoned expert with nearly 30 years of experience working with industry giants like Novartis, Biogen, Thermo Fisher, and Merck. Scott shares insights on cell culture technology, mRNA vaccines, and the challenges and innovations in scaling biotech facilities. Discover the impact of collaboration and how organizations like the International Society for Pharmaceutical Engineering (ISPE) are transforming the landscape.Chapters :00:00 - Introduction to Vaccine Technologies00:14 - Importance of Collaboration in Pharma Manufacturing00:22 - The Role of Technology Ecosystems00:30 - Scott's Experience with ISPE00:46 - Motivation Behind Pharma & Biotech Careers01:09 - Welcoming Scott to Life Sciences 36001:19 - Scott's Background & Industry Experience01:45 - Integrating Technology in Pharmaceutical Facilities01:59 - Scott's Current Role & Unique Challenges02:18 - Interview Kickoff: Scott's Career Insights03:11 - The Evolution of Drug Manufacturing03:39 - Insights for Non-Pharma Audiences03:59 - Changes in Vaccine Manufacturing Over the Years04:40 - mRNA Technology and Its Impact05:05 - Encouraging Viewers to Subscribe05:59 - Driving Innovation in Manufacturing Facilities07:01 - Challenges in Scaling New Therapies08:17 - Overcoming Challenges in New Tech Implementation09:03 - The Role of Technology Vendors10:08 - Advancements in Manufacturing Technology11:02 - Evolution of Biotech Processes12:09 - Consulting in Cell and Gene Therapy13:02 - The Infancy of Cell and Gene Therapy13:23 - Introduction to SoulVentum14:01 - Separation from 3M and Vision for SoulVentum15:01 - Scott's Role at SoulVentum15:33 - Scott's Contributions to ISPE17:18 - Identifying Award-Winning Facilities18:39 - ISPE Facility of the Year Criteria20:18 - Global Reach of ISPE Submissions21:41 - Geographical Insights Post-Pandemic22:47 - The Role of ISPE in Pharma Collaboration23:31 - ISPE Communities of Practice24:47 - Forums & Conferences by ISPE26:19 - Local ISPE Chapters & Regional Support26:58 - Scott's Take on Industry Networking28:05 - The Importance of Professional Networks29:05 - Advice on Building a Career in Pharma30:21 - Scott's Mission in the Industry31:42 - Personal Impact of the Work in Pharma32:26 - Patient Stories and Their Motivational Impact33:22 - Closing Thoughts & How to Connect with Scott

Welcome to another episode of Life Sciences 360! Today, we're diving into the intricate world of life sciences leadership with a special guest who's worn nearly every hat in the industry—Taggart McGurrin. Starting in finance, transitioning to law, and tackling leadership roles across strategy, operations, and regulatory affairs, Taggart McGurrin brings a unique perspective on how to navigate the high-stakes environment of life sciences.In this episode, we cover:The Complexities of Life Sciences: Taggart McGurrin explains why this industry has more risk areas than most, from regulatory hurdles to financial pressures.Triple Threat in Leadership: Discover Taggart's approach to balancing “What you have, what you need, and what you want” for effective decision-making.Navigating the CFO/COO Role: Taggart shares insights on managing dual executive roles, emphasizing the importance of detail, resilience, and creative pragmatism.Overcoming Financial Hurdles: Insights on cash flow challenges and how proper planning and investor relations drive success.Unique Challenges in Life Sciences: The balancing act between meeting regulatory demands and fostering innovation.Whether you're a leader in life sciences, considering a C-level role, or just curious about this industry, this episode is packed with practical insights!Chapters: 00:00 - Intro01:00 - The Life Sciences Landscape03:30 - Importance of Patient-Centric Leadership10:00 - The Role of Detail in Executive Leadership17:00 - Managing Financial Pressures in Life Sciences22:00 - Navigating Regulatory Challenges27:00 - Raising Capital in Life Sciences29:00 - Final TakeawaysIf you're looking to understand the unique challenges and leadership dynamics within life sciences, this is a must-watch! Don't forget to subscribe for more content on leadership, innovation, and life sciences trends.

In this episode of Life Sciences 360, host Harsh Thakkar sits down with Marc Sheetz, Associate Dean of Research at Midwestern University's College of Pharmacy, to discuss the growing concern of antimicrobial resistance and the field of pharmacometrics. Marc sheds light on how pharmacometrics is shaping the future of medicine by using predictive models to personalize dosing, making drug treatments more effective while reducing toxicity. This episode dives deep into the intersection of pharmacometrics, AI, and machine learning, revealing how the future of patient care and treatment is rapidly evolving. Marc also shares insights from his current research in the infectious disease space, including his work with pediatric ICU patients.Chapters:00:00 Introduction00:03 Antibiotic Toxicity and Population Models01:02 The Importance of Antibiotics and Public Health Challenges01:22 Introduction to Pharmacometric Science03:12 Using Data in Medicine for Future Predictions06:01 Tailoring Drug Dosages for Individuals09:36 The Global Variation in Drug Dosages and Challenges14:44 The Future of Personalized Medicine and Precision Dosing21:39 The Intersection of AI, Machine Learning, and Pharmacometrics26:35 The Role of Technology in Medicine30:01 How Dosing Software and AI Are Enhancing Patient Care36:54 Innovation and Research Trends in Medicine- Connect with Marc Sheetz on Twitter: (https://twitter.com/IDPharmacometrics)  - Learn more about Midwestern University: (https://www.midwestern.edu)  - Follow Life Sciences 360 on LinkedIn (https://www.linkedin.com/company/life-sciences-360)--- Subscribe to our podcast for more insights on life sciences: 

Imagine knowing how your body will respond to a medication before you even take it! In this episode, Harsh Thakkar interviews Sarah Rogers, co-founder and president of the American Society of Pharmacovigilance (ASP) and an Assistant Professor at Texas A&M. Together, they dive deep into the fascinating world of pharmacogenomics—how your genetic makeup affects your response to medications. They discuss the challenges of pharmacogenomic testing, real-world examples of adverse drug reactions, and the future of personalized medicine. Chapters:00:00 - Intro00:16 - Breaking Down Pharmacogenomics01:39 - Guest Introduction: Sarah Rogers  02:18 - Explaining Pharmacogenomics to a Child03:24 - Sarah's Start in Pharmacogenomics  04:54 - The Power of Pharmacogenomics07:00 - Pharmacogenomics Clinic at Texas A&M  09:02 - Challenges of Standardizing PGX Testing11:14 - The Ideal Pharmacogenomics Workflow13:39 - Real-World Example of PGX in Action15:44 - Importance of Integrating PGX into EHR 20:24 - AI and Digital Twins in Pharmacogenomics21:52 - Lessons Learned in Pharmacogenomics24:46 - Looking to the Future of Personalized Medicine28:18 - Final Takeaway  30:22 - Outro Connect with Sarah Rogers:- LinkedIn: (https://www.linkedin.com/company/american-society-of-pharmacovigilance)  - STRIPE Initiative LinkedIn: (https://www.linkedin.com/company/stripe-pharmacogenomics)  - Twitter: (https://twitter.com/amsocietypharm)  - Newsletter signup for the American Society of Pharmacovigilance:  https://www.stopadr.org/Here are links for some of the information that I mentioned during our meeting:- STRIPE Annual Meeting and Consensus Workshop - (https://www.usp.org/node/289416) - Collaborative Communities: Addressing Health Care Challenges Together(https://www.fda.gov/about-fda/cdrh-strategic-priorities-and-updates/collaborative-communities-addressing-health-care-challenges-together)- Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community - (https://stopadr.org/stripe)- Texas A&M Interprofessional Pharmacogenomics (IPGx) Clinic - (https://ibt.tamu.edu/cores/Texas%20ClinicoGenomics/Texas%20ClinicoGenomics.html)- National Action Plan for Adverse Drug Event Prevention - (https://health.gov/sites/default/files/2019-09/ADE-Action-Plan-508c.pdf)- Figure showing Stakeholders Involved in the Lifecycle of a Pharmacogenomics Test(https://www.nature.com/articles/s41397-024-00345-y/figures/1)- Subscribe to our podcast for more insights on life sciences: 

In this episode, Harsh Thakkar welcomes David Ormesher, CEO of CG Life, a leading marketing agency in the life sciences and pharmaceutical sectors. David shares over 30 years of experience in life science marketing and storytelling. From startups to large enterprises, CG Life helps companies blend complex science with compelling stories to resonate with patients, healthcare professionals, and investors.David discusses his entrepreneurial journey, how CG Life specializes in biopharmaceutical marketing, and key insights into building an agency that bridges the gap between science and storytelling. He also shares the strategic importance of focusing on the patient journey, how to scale marketing for companies of all sizes, and the role of digital platforms in the ever-evolving landscape of pharma and biotechnology marketing.Chapters:00:00 - Introduction  00:09 - The Importance of Storytelling in Life Sciences  01:00 - David's Journey into Life Science Marketing  02:00 - Starting CG Life and its Evolution  05:00 - Combining Science and Storytelling  08:00 - Challenges and Opportunities in Biopharma Marketing  10:00 - CG Life's Growth Strategy and Key Acquisitions  13:00 - Leveraging Social Media and Digital Platforms in Pharma  17:00 - Storytelling for Different Audiences: Patients, HCPs, and Investors  22:00 - Case Study: Terran Biosciences – Building Market Visibility  24:00 - Case Study: Novo Nordisk – Digital Customer Experience for HCPs  30:00 - Advice for Entrepreneurs Starting a Marketing Agency  34:00 - Lessons Learned from David's Entrepreneurial Journey  36:00 - Building a Strong Team for Success  37:00 - Final Thoughts and Call to Action  Don't forget to subscribe and share your thoughts in the comments! Let us know what topics or guests you want to see next.---Links:Visit CG Life: (https://www.cglife.com)  Connect with David Ormesher on LinkedIn: (https://www.linkedin.com/in/davidormesher)- Subscribe to our podcast for more insights on life sciences: 

In this episode, we dive deep into a fascinating topic worm-derived therapeutics with our special guest Andrea, the founder and CEO of Holoclara. Did you know that autoimmune and allergic diseases were rare before the 1900s? What changed? Andrea shares groundbreaking insights into how worms, which have lived inside humans for millions of years, secrete molecules that could balance our immune system and help us tackle these diseases.From her early research days at Caltech to founding Holoclara, Andrea walks us through her journey, including:Chapters:  00:00 - The History of Autoimmune Diseases01:24 - Why Watch This Video?02:36 - Andrea's Research Background05:49 - The Turning Point: Entrepreneurship and Therapeutics09:02 - Worms and Human Health: The Therapeutic Connection11:32 - Worm Communication and Therapeutics15:24 - The Industrial Revolution and Autoimmune Diseases19:33 - How Worm-Derived Therapeutics Work21:33 - Overcoming Challenges in Biotech24:21 - The Future of Worm-Derived Therapeutics25:48 - Studying Different Worm Species26:57 - Life Outside Research29:29 - Final Takeaway: Embracing Feedback and OpportunityAndrea also discusses the personal and scientific breakthroughs that led her to create Holoclara, a company dedicated to harnessing worm-derived molecules for modern medical solutions. Learn how roundworms evolved to produce tools that harmonize our immune system, and how these ancient organisms may hold the key to treating modern diseases.If you're intrigued by this incredible scientific journey and its implications for health, don't miss this episode!

Learn how misfolded proteins trigger cascading effects in the brain, leading to these devastating conditions, and how early detection can change the trajectory of treatment. Whether you're curious about ALS, Parkinson's, Dementia, or the role of molecular diagnostics.In this insightful episode, we dive deep into the world of neurodegenerative diseases, focusing on conditions like ALS, Parkinson's disease, Alzheimer's, and Dementia. Our guest, Russ Lebovitz, co-founder of Amprion, explains their groundbreaking work in detecting misfolded proteins, the primary culprits behind these diseases. From early diagnosis to understanding the role of technology and AI in healthcare, we explore how Amprion's revolutionary diagnostic tools are shaping the future of brain health.Chapters:00:00 - Introduction to the episode  00:13 - Amprion's unique approach to neurodegenerative diseases  00:40 - Misfolded proteins as the root cause  01:25 - Background of the guest, Russ Lebovitz  02:56 - Amprion's elevator pitch and core focus  03:59 - How Amprion detects misfolded proteins  05:57 - Misfolded proteins and their role in diseases  07:45 - The amplification process used by Amprion  09:27 - The causes of protein misfolding  12:29 - How Amprion's test works  14:05 - Early diagnosis through amplification  17:27 - Availability and expansion of Amprion's technology worldwide  21:03 - The role of AI in diagnosing neurodegenerative diseases  23:47 - Challenges in integrating AI into healthcare  27:17 - Predictions for future breakthroughs  32:35 - Collaboration between diagnostic tools, AI, and drug development  36:23 - Conclusion and closing remarks   

Welcome to episode 063 of Life Sciences 360.We dive deep into the groundbreaking role of AI in healthcare and life sciences with Shweta from Google Cloud. Learn how AI is accelerating drug discovery, enhancing patient care, and revolutionizing rare disease research. If you're passionate about the intersection of technology and health, this is a must-watch conversation!

Welcome to episode 062 of Life Sciences 360.In this episode, we dive into an engaging conversation with Tom, a seasoned consultant, on how to recognize the early signs of burnout, foster a healthy and innovative work environment, and implement agility in regulated industries. Tom shares practical strategies for leaders and consultants alike to maintain performance without compromising mental well-being. Whether you're a business leader, consultant, or anyone looking to improve work-life balance, this video is packed with actionable advice!Chapters:00:00 – Introduction  00:34 – Life as a Consultant: What It's Really Like  01:00 – Burnout in Consulting vs. 9-to-5 Jobs  02:06 – Recognizing Early Signs of Burnout  03:56 – Overpromising and Work-Life Balance  04:31 – 3 Key Strategies to Prevent Burnout  05:52 – Managing Priorities and Influencing Decisions  09:55 – The Sandbox Approach to Innovation  12:02 – Innovation in Regulated Industries  14:30 – Encouraging Employee Experimentation  17:39 – Real-World Examples of Innovation Success  18:20 – Leadership Qualities That Promote Innovation  21:50 – Systems for Capturing and Reviewing Ideas  26:03 – Challenges of Implementing Agile in Regulated Industries  29:00 – Countering Opposition to Agile  33:01 – The Best Part of Consulting: Tom's Take  34:48 – How to Connect with Tom  35:17 – Final Thoughts on Preventing BurnoutConnect with Tom:LinkedIn: https://www.linkedin.com/in/tom-siebeneicher/  Spotify: https://open.spotify.com/episode/0aXLVMPZtFh79TKle9aN9y?si=4Xswz8zGTeKnkkogqB0BTg  YouTube: https://www.youtube.com/playlist?list=PL3RKCnY-ES1kNaNP7WnQ37uiweOEbjB7OLinks:*Harsh Thakkar LinkedIn ( https://www.linkedin.com/in/harshvthakkar/ )*Listen to this episode on the go! 

Welcome to episode 061 of Life Sciences 360.In this episode of Life Sciences 360, host Harsh Thakkar sits down with Kevin Sharp, Senior Vice President and Head of Global Sales at Samsung Biologics. They dive deep into the evolving CDMO industry, the importance of agility, innovation, and the strategic growth pillars that are driving success at Samsung Biologics. Kevin shares his journey from government roles to life sciences, discusses the rapid advancements in ADCs, and explores how emerging technologies like AI are reshaping the industry.Chapters:00:00 - Introduction  00:02 - Overcoming Roadblocks in the Industry  00:10 - Flexibility and Agility in Implementation  00:18 - Innovating Through Challenges  00:24 - The Mission of Life Sciences and Pharma  00:52 - The Speed Factor in Pharma Development  01:26 - Introduction to Kevin Sharp and Samsung Biologics  02:00 - Kevin Sharp's Career Journey to Life Sciences  03:29 - Transition from Pharma to CDMO Space  05:29 - The Rapid Growth of the CDMO Industry  07:14 - Key Challenges in Transitioning to a CDMO Role  09:22 - The Boom of CDMOs and Their Impact  11:32 - Regulatory Challenges and CDMO Expertise  13:48 - Strategic Partnerships with Top Pharma Companies  15:59 - The Importance of Diversification and Capability Growth  18:25 - Building Long-Term Partnerships with CDMOs  22:04 - Adapting to Roadblocks with Agility  23:59 - ADC Market Insights and Samsung Biologics' Strategy  28:24 - The Future of Life Sciences: New Modalities and Technologies  30:27 - Leveraging Emerging Technologies like AI in CDMOs  34:52 - Leadership and Operational Excellence in Life Sciences  39:20 - Working at Samsung Biologics  41:17 - Final Thoughts and How to Connect with Kevin SharpConnect with Kevin Sharp:Kevin's LinkedIn: (https://www.linkedin.com/in/kevinsharp)  Samsung Biologics: (https://www.samsungbiologics.com/)Don't forget to like, share, and subscribe for more insightful conversations on achieving success in life sciences and beyond!---Links:*Harsh Thakkar LinkedIn ( https://www.linkedin.com/in/harshvthakkar/ )*Listen to this episode on the go! 

Welcome to episode 060 of Life Sciences 360.In this episode of Life Sciences 360, host Harsh Thakkar sits down with Dr. Robin Odegaard, a high-performance business psychologist and professional confidant, to discuss the hidden struggles that come with success. They dive deep into topics like imposter syndrome, self-sabotage, complex priorities, and the loneliness that often accompanies high achievement. Dr. Robin shares actionable strategies and insights from her extensive work with lawyers, biotech CEOs, neurosurgeons, and more.Chapters:00:00 - Introduction  00:33 - The Voice in Your Head & Head Trash  01:29 - Dr. Robin's Journey into High-Performance Psychology  02:48 - Understanding Self-Sabotage and How It Manifests  05:10 - The Loneliness of Success: Why It's “Lonely at the Top”  07:23 - Techniques to Recognize and Combat Self-Sabotage  11:22 - Managing Complex Priorities with the “Foresting Project”  15:48 - Time Audits & Delegation for Effective Time Management  18:41 - The Challenge of Letting Go for High Performers  20:58 - Working with Diverse Clients: From Athletes to CEOs  23:03 - Emotional State Management for Better Communication  27:28 - The Isolation of Success & Who High Achievers Talk To  33:47 - Final Thoughts & Advice for Listeners  35:58 - ConclusionConnect with Dr. Robin Odegaard:- Website: (https://www.mentalmacgyver.com)  - LinkedIn: (https://www.linkedin.com/in/robinodegaard)  - YouTube: (https://www.youtube.com/@DrRobin)Watch Next: Take Out the Head Trash | How to Fight the Demons Keeping You Awake at 3 a.m(https://youtu.be/Kx12TTCoojg?si=BDsG4KLZOVMO71HW)Don't forget to like, share, and subscribe for more insightful conversations on achieving success in life sciences and beyond!---Links:*Harsh Thakkar LinkedIn ( https://www.linkedin.com/in/harshvthakkar/ )*Listen to this episode on the go! 

Welcome to episode 059 of Life Sciences 360.In this episode of Life Sciences 360, Harsh Thakkar is joined by John Finn, Chief Scientific Officer at Tome Biosciences. John shares his inspiring journey of overcoming challenges, like his stutter, while making groundbreaking strides in gene therapy. They dive deep into Tome's unique technology, PGI (Programmable Genomic Integration), which is revolutionizing how large-scale gene insertions are done with pinpoint accuracy. Learn how Tome Biosciences is leading the charge in curing genetic disorders and advancing cell therapy with cutting-edge science.Chapters:00:00 - Introduction to the Episode00:29 - The Vision Behind Gene Therapy01:13 - John's Journey and Challenges with Stuttering03:14 - How Stuttering Shaped John's Career in Science05:43 - Introduction to Tome Biosciences07:02 - The Origins of Tome and Founding Vision09:49 - Why Large-Scale Gene Editing Matters14:12 - How Tome's PGI Technology Works20:29 - What Sets Tome Apart in Gene Therapy24:31 - Future Milestones for Tome Biosciences30:49 - Overcoming Challenges in Genomic Integration36:47 - The Power of Team Culture at Tome Biosciences40:20 - Advice for Aspiring Scientists and Entrepreneurs42:52 - Where to Connect with John Finn and Learn More About Tome- Follow John Finn: *Linkedin - ( https://www.linkedin.com/in/jonathan-john-finn-8b3bb23/ ) *Tome Bio Linkedin -  ( https://www.linkedin.com/company/tome-biosciences/ ) * Tome Bio Website- ( https://tome.bio/ )---Links:*Harsh Thakkar LinkedIn ( https://www.linkedin.com/in/harshvthakkar/ )*Listen to this episode on the go! 

Welcome to episode 058 of Life Sciences 360.In this insightful episode of Life Sciences 360, hosted by Harsh Thakkar, we explore the dynamic world of Contract Development and Manufacturing Organizations (CDMOs) with Ryan Memmer, Manager of Quality Control and Product Development at Singota Solutions. Ryan shares his journey from working at large pharmaceutical companies to leading a growing team at Singota, a CDMO focused on phase one drug development. He provides a behind-the-scenes look at the challenges and opportunities in this fast-paced environment, and how Singota is uniquely positioned to support early-stage pharmaceutical companies.Chapters:00:00 - Introduction: Ryan Memmer's background and role at Singota.01:10 - Career Journey: Transition from large pharma to a smaller CDMO.03:18 - Challenges in CDMO Culture: Overcoming fast-paced industry challenges.06:59 - Knowledge Sharing and Trust: Building trust in early phase work.08:03 - Singota's Unique Strengths: What sets Singota apart in the CDMO space.11:32 - Importance of Diverse Backgrounds: Value of diverse skill sets within the team.13:04 - Client Collaboration: Singota's approach to custom client solutions.17:25 - Broad Client Portfolio: Overview of Singota's diverse client base.20:03 - Preparing for Commercialization: Adapting to phase three and commercial standards.24:19 - Singota's Global Expansion: Expanding operations into international markets.25:56 - Advice for Aspiring Scientists: Tips for those starting out in QC or product development.28:22 - Continuous Learning: Emphasizing the importance of cross-functional learning.31:11 - Closing Thoughts: Final thoughts from Ryan Memmer and how to connect.- Follow Ryan Memmer:- Singota Solutions Official Website: (https://singota.com/)- Follow Ryan Memmer on LinkedIn: (https://www.linkedin.com/in/memmer-ryan/)Key Takeaways:- Understanding the unique challenges of working in a CDMO environment.- The importance of knowledge sharing and trust in client relationships.- Singota's strengths in serving early-stage pharmaceutical companies.- The value of continuous learning and diverse skill sets in the industry.

Welcome to episode 057 of Life Sciences 360.In this special episode of Life Sciences 360, hosted by Harsh Thakkar, we dive into the fascinating world of bioidentical hormone replacement therapy (BHRT) with Dr. Greg Brannon, Medical Director and Founder of Optimalbio. Celebrating National Men's Health Education and Awareness Month, Dr. Brannon shares his expertise on the benefits of BHRT, the science behind hormone therapy, and the insights from his Amazon bestseller book, "Restore."Chapters:00:01 - Introduction: Discussing the importance of health education.00:37 - The significance of hormone health.01:30 - The journey behind Dr. Brannon's book "Restore."02:52 - The role of testosterone and hormones in overall health.03:43 - Dr. Brannon's medical background and shift to hormone therapy.05:20 - Understanding bioidentical hormone replacement therapy (BHRT).06:20 - The science behind hormone therapy and its impact on chronic diseases.08:19 - Broader implications of hormone imbalances in society.09:41 - Practical advice for optimizing hormone levels.10:42 - The impact of modern lifestyle on hormone health.12:09 - Hormone therapy in practice and success stories.15:11 - The future of Optimalbio and its expansion plans.16:19 - Closing remarks and contact information for further learning.- Follow Dr. Greg Brannon: *YouTube:(https://www.youtube.com/channel/UCRWEkzCUh_CHIBGB5dae5rw) *Instagram - (https://www.instagram.com/optimalbio/) *TikTok - (https://www.tiktok.com/@optimobio) *Linkedin - (https://www.linkedin.com/company/optimal-bio/) * OptimoBio Website- (https://optimalbio.com/)Key Takeaways:- Understanding the crucial role of hormones in maintaining overall health.- The benefits of bioidentical hormone replacement therapy (BHRT).- Practical tips for maintaining optimal hormone levels through lifestyle changes.- Success stories from patients who have benefited from hormone therapy.---Links:*Harsh Thakkar LinkedIn ( https://www.linkedin.com/in/harshvthakkar/ )*Listen to this episode on the go! 

Welcome to episode 056 of Life Sciences 360.Welcome to another episode of Life Sciences 360! In this episode, Harsh Thakkar is joined by Joel Eichmann, co-founder and managing director of Green Elephant Biotech. Green Elephant Biotech is a trailblazer in the biotech industry, focusing on sustainability and using plant-based materials to create innovative products. Joel shares the fascinating journey of how Green Elephant Biotech started, the challenges they faced, and the future of sustainable biotech.Chapters:00:00 - Introduction01:23 - Welcoming Joel Eichmann02:39 - Origins of Green Elephant Biotech05:15 - From Concept to Commercial Product07:30 - Early Challenges and Strategies10:02 - Advice for Aspiring Biotech Entrepreneurs12:33 - Incorporating Sustainability15:01 - Hiring and Building the Team18:37 - Understanding the Life Sciences Industry21:19 - Balancing Innovation and Sustainability24:05 - Industry Challenges and Opportunities27:34 - Generating New Product Ideas30:13 - Recognition and Awards31:31 - Long-term Goals and Automation34:28 - The Future of Automation in Biotech36:06 - Where to Learn More About Green Elephant Biotech37:44 - Final Thoughts on SustainabilityConnect with Joel Eichmann -Green Elephant Biotech: (https://www.greenelephantbiotech.com/)Joel Eichmann: (https://www.linkedin.com/in/joel-eichmann/)Harsh Thakkar: (https://www.linkedin.com/in/harshvthakkar/)*Listen to this episode on the go! 

Welcome to episode 055 of Life Sciences 360.In this episode of Life Sciences 360! In this episode, Harsh sits down with Dr. Kate Broderick, Chief Innovation Officer at Maravai Life Sciences. Dr. Broderick shares her journey from academia to leading innovation in the biotech industry, discusses the pivotal role of Clean Cap technology in COVID-19 vaccines, and explores the future applications of mRNA. Learn about the collaborative spirit at Maravai and the exciting developments in genomic medicine, personalized cancer vaccines, and more. Join Harsh Thakkar in an insightful conversation with Dr. Kate Broderick, the Chief Innovation Officer at Maravai Life Sciences. Discover the future of mRNA, the role of Clean Cap technology in COVID-19 vaccines, and the innovative work happening at Maravai and its subsidiaries.Chapters:00:00 - Introduction00:03 - Dr. Kate Broderick's Career Background00:38 - Overview of Maravai Life Sciences01:22 - Starting in Life Sciences and Career Journey03:17 - Role of Chief Innovation Officer04:02 - Turning Ideas into Innovations05:22 - Blending Research, Development, and Leadership07:40 - Working at Maravai and Cross-functional Leadership08:05 - Clean Cap Technology and its Impact09:15 - Maravai's Business Units and Synergies10:25 - Clean Cap in COVID Vaccines11:48 - Future Applications of mRNA13:31 - Overcoming Challenges with mRNA15:09 - Improving Stability and Targeting Specific Cells17:49 - Importance of Collaboration in Science19:25 - Maravai's Approach to Partnerships and Collaborations23:12 - New mRNA Manufacturing Facility25:22 - Functional Segmentation of Facilities27:35 - Recognition as a Top Biotech Executive29:46 - Exciting Areas in Life Sciences for the Future31:50 - Potential of CRISPR and Base Editing33:19 - Closing Remarks and Contact InformationConnect with Dr. Kate Broderick:- Kate Broderick (https://www.linkedin.com/in/katebroderick)- Maravai Life Sciences: (https://www.maravai.com)- TriLink Biotechnologies: (https://www.trilinkbiotech.com)Stay Tuned for More Episodes:Subscribe to Life Sciences 360 for more interviews and insights from leaders in the biotech and life sciences industry.---#Biotech #LifeSciences #ResearchAndDevelopment #BiotechIndustry #FutureOfMedicine #ScienceAndTechFor more, check out the podcast website - www.lifesciencespod.com

Welcome to episode 054 of Life Sciences 360.In this episode of Life Science 360 ,Today, we are thrilled to have Lisa Sellers, the CEO of Vector Labs, as our special guest. Lisa shares her incredible journey from working at big names like Thermo Fisher and 10x Genomics to leading Vector Labs, a trusted manufacturer of reagents and critical components in the life sciences sector.In this episode, we dive deep into:- Lisa's transition from being an industry professional to becoming a CEO- The unique challenges and benefits of working in smaller companies- Vector Labs' strategic acquisitions and mergers to expand their product portfolio- The impact of Vector Labs in the pharmaceutical, diagnostic, and academic sectors- Lisa's passion for mentorship and her efforts to inspire the next generation in STEM fieldsChapters :00:00 - Introduction00:41 - Welcome Lisa Sellers01:12 - Lisa's Career Journey02:37 - Transition to CEO05:00 - Comparing Big Companies to Smaller Companies09:28 - Vector Labs' Product and Service Overview14:25 - Recent Acquisitions and Expansions17:20 - Role of Private Equity in Vector Labs20:28 - Challenges in Protein and Glycan Detection23:54 - Vector Labs' Diverse Customer Base26:59 - Managing Priorities and Resources29:00 - Vision for Vector Labs in the Next 5 Years32:39 - Lisa's Mentorship and Community Involvement37:17 - Key Leadership Qualities in STEM41:28 - Final Thoughts and ClosingStay tuned and don't forget to subscribe for more in-depth conversations with leading scientists and innovators in the life sciences field!----- Links:*Lisa Sellers: (https://www.linkedin.com/in/lisa-sellers/)*Vector Labs: (https://www.linkedin.com/company/vector-laboratories/)*Harsh Thakkar LinkedIn ( https://www.linkedin.com/in/harshvthakkar/ )*Listen to this episode on the go! 

Welcome to episode 053 of Life Sciences 360.In this episode of Life Science 360, our host Harsh Thakkar sits down with Brian Cosgrove, Principal Scientist at Tune Therapeutics. Brian dives deep into the fascinating world of epigenetics and its role in developing therapies for complex diseases. He shares insights on how Tune Therapeutics is leveraging the power of the epigenome to create innovative treatments, particularly focusing on their work with hepatitis B and the promising potential of their tempo platform.Chapters:00:00 - Introduction00:02 - Understanding Cell Differentiation and Gene Regulation00:37 - Welcome Brian Cosgrove from Tune Therapeutics01:15 - Brian's Transition from Duke University to Tune Therapeutics02:03 - The Basics of Epigenetic Tuning02:38 - How Epigenetics Determines Cell Function03:55 - The Role of the Epigenome in Gene Expression05:06 - The Complexity of the Human Body and Scientific Research06:12 - Deep Dive into Hepatitis B (HBV)06:57 - Current Treatments for Chronic Hepatitis B08:32 - The Unmet Need in Hepatitis B Treatment09:09 - Brian's Career Path and Decision to Join Tune Therapeutics12:03 - Growth and Evolution of Tune Therapeutics15:25 - Challenges and Rewards of Joining an Early-Stage Company17:49 - Introduction to the Tempo Platform19:04 - How Tempo Platform Works with HBV20:32 - Epigenetic Regulation of HBV23:20 - Future Applications of Epigenetic Tuning24:38 - Timeline for Tune 401 Clinical Trials26:08 - Anticipated Challenges and Solutions27:20 - Partnering for Manufacturing and Delivery28:32 - The Broader Field of Epigenetic Therapies30:21 - Potential Global Impact of Epigenetic Therapies32:12 - The Most Rewarding Part of Brian's Work33:01 - The Personal Side of Working in Life Sciences35:10 - Final Thoughts and Future Outlook for Tune Therapeutics36:09 - Closing Remarks and How to Connect with BrianStay tuned and don't forget to subscribe for more in-depth conversations with leading scientists and innovators in the life sciences field!----- Links:*Brian Cosgrove LinkedIn (https://www.linkedin.com/in/brian-cosgrove-171b926/)*Tune Therapeutics LinkedIn (https://www.linkedin.com/company/tunetx/ )*Tune Therapeutics website (https://tunetx.com/)*Harsh Thakkar LinkedIn ( https://www.linkedin.com/in/harshvthakkar/ )*Listen to this episode on the go! 

Welcome to episode 052 of Life Sciences 360.In this episode, of Life Sciences as we dive into the fascinating world of psychedelic therapeutics with Dr. Sam Clark, the Chief Executive Officer of Terran Biosciences. Dr. Clark shares his journey of founding Terran Biosciences, motivated by the need for better treatment options for psychiatric and neurological disorders. Discover how Terran Biosciences is leveraging a tech company structure to accelerate drug development, utilizing AI in imaging, and pioneering innovative prodrugs. Learn about the company's groundbreaking work in developing psychedelics without hallucinations and their mission to make these therapies affordable and accessible to patients. Subscribe for more insightful conversations with leaders in the biotech and life sciences industries!Chapters:00:00 - Introduction00:12 - Dr. Sam Clark's Motivation and Background01:00 - Founding Terran Biosciences01:35 - Challenges in Psychiatric and Neurological Treatment Development02:55 - Innovating with a Tech Company Structure03:18 - Use of AI and Drug Development Strategies04:18 - Slow Translation of Research to Therapies05:50 - Development of New Prodrugs07:12 - Explanation of Prodrugs08:49 - Terran's Lead Assets for Psychotic Disorders10:16 - Creating Long-Acting Prodrugs12:16 - Addressing Regulatory Hurdles in Psychedelic Research14:20 - Pipeline Overview and Future Plans16:13 - Importance of Collaboration in Psychedelic Research17:58 - The Rise of Big Pharma Interest in Neuroscience20:14 - Addressing Stigma Around Psychedelics23:02 - Overcoming Regulatory Challenges26:31 - Trends in Psychedelic Funding31:48 - Making Medications More Accessible37:00 - Impact of Psychedelic Approvals on the Industry38:20 - Focus on Patient-Centric Approaches41:11 - Final Thoughts and Future AnnouncementsFollow Terran Biosciences on LinkedIn and X, and visit their website for the latest updates and announcements. -----Links:- [Terran Biosciences on LinkedIn](https://www.linkedin.com/company/terran/)- [Terran Biosciences on X](https://x.com/terranbio)- [Dr. Sam Clark on X](https://x.com/neonneurons)- [Terran Biosciences Website](https://terranbio.com)- [Tera XT Website](https://teraxt.com)For more, check out the podcast website - www.lifesciencespod.com

Welcome to episode 051 of Life Sciences 360.We welcome Howard McLeod, a distinguished expert in precision medicine and pharmacogenomics. Howard shares his profound journey into the world of personalized medicine, emphasizing the significant impact of individualized treatments on cancer patients. From groundbreaking gene discoveries to advising cutting-edge biotech companies, Howard's work underscores the value of targeted therapies and their potential to transform patient outcomes.Howard also discusses his current roles, including his position as the Center Director for Precision Medicine and Functional Genomics at Utah Tech and his advisory role in several companies. He shares insights into exciting projects aimed at improving drug response predictions and mental health treatments for university students through pharmacogenomics.Chapters 00:00 - Introduction and Guest Welcome01:00 - The Importance of Experimental Therapies02:00 - Career Inspiration and Key Moments04:00 - Mentors and Lessons Learned06:00 - Practical Applications of Research08:00 - Staying Grounded in Patient Care10:00 - Current Roles and Projects12:00 - Addressing Mental Health in Students14:00 - Integrating Technology in Medicine18:00 - Simplifying Complex Medical Information22:00 - Reflections on Technological Advancements26:00 - Embracing Change and New Challenges30:00 - Final Thoughts and Future Outlook36:00 - Closing Remarks and Contact InformationThis episode is a treasure trove of insights for anyone interested in precision medicine, pharmacogenomics, and the future of healthcare. Don't miss Howard McLeod's inspiring journey and the valuable lessons he shares!-----Links:*Dr. Howard McLeod LinkedIn ( https://www.linkedin.com/in/howard-mcleod-90866a12/)*Harsh Thakkar LinkedIn (https://www.linkedin.com/in/harshvthakkar/)*Listen to this episode on the go!

Welcome to episode 050 of Life Sciences 360.In this episode, Harsh Thakkar chats with Tony Martignetti, a top leadership development voice on LinkedIn and an advisor to numerous tech and life sciences executives. Tony shares his insights on inspired leadership, the importance of investing in people, and how to unlock potential within teams. They also discuss the concept of flashpoints in both personal and organizational contexts and the value of embracing divergent thinking in the workplace.Chapters:00:00 Introduction to Tony Martignetti and Leadership Development01:04 Advocating for Inspired Leadership02:23 Influences: Henry Tamir and “No Rules, Rules” Book04:37 Investing in People: Beyond Pedigree06:19 Authentic Leadership: Bringing Your Whole Self to Work09:40 The Core Model: Encouraging Authenticity in Teams11:33 Identifying and Aligning Personal and Organizational Flashpoints13:04 Overcoming Barriers: Personal Stories and Career Challenges16:13 Flashpoints in Organizations: Examples and Insights19:34 Embracing Divergent Thinking for Innovation25:30 Convergent Hearts: Building Connection and Understanding30:46 Practical Tips for Leaders to Foster Innovation and Growth35:21 Specialist vs. Generalist: Expanding Skills and Knowledge39:36 Key Takeaways: Expanding Vision and Narrowing Focus-----Links:*Tony Martignetti LinkedIn (https://www.linkedin.com/in/tonymartignetti1/)*Tony Martignetti Website (https://ipurposepartners.com/)*Harsh Thakkar LinkedIn (https://www.linkedin.com/in/harshvthakkar/)*Listen to this episode on the go!

Welcome to episode 049 of Life Sciences 360.In this episode of Life Sciences 360, host Harsh Thakkar welcomes Jesse Mendelsohn, Senior Vice President at Model N. Jesse delves into the intricacies of revenue optimization and compliance within the pharmaceutical industry. He shares insights on how Model N's platform aids pharmaceutical companies in navigating complex pricing, regulatory challenges, and government negotiations.Chapters :0:00 - Introduction1:30 - Welcoming Jesse Mendelsohn2:00 - Jesse's Journey with Model N6:00 - Evolution of Pharma Pricing and Compliance8:30 - Challenges in Commercial Contracting12:00 - Regulatory Side of Pharma Pricing14:30 - Impact of Government as a Major Drug Purchaser16:00 - Inflation Reduction Act Overview19:00 - Medicare's Right to Negotiate Drug Prices21:00 - Aftershocks of the Inflation Reduction Act23:30 - Key Takeaways for Pharma Executives26:00 - Impact on Drug Development Strategy28:00 - Generics and Biosimilars Market Impact30:30 - Positive Outcomes of the Inflation Reduction Act32:00 - What's Next for Model N36:00 - Importance of Accurate Data in Pricing38:30 - Closing Remarks and Connect with Jesse----- Links:* Jesse Mendelsohn LinkedIn (https://www.linkedin.com/in/jessedm/)* Model N LinkedIn (https://www.linkedin.com/company/modeln/)* Model N website (https://www.modeln.com/)*Harsh Thakkar LinkedIn ( https://www.linkedin.com/in/harshvthakkar/  )*Listen to this episode on the go!

Welcome to episode 048 of Life Sciences 360.In this episode, Sharmeen discuss the current one-size-fits-all approach in healthcare and the need for precision dosing. Sharmeen explains how DoseMe platform simplifies complex dosing methods at the bedside, benefiting both clinicians and patients. Sharmeen also touch on the integration with electronic health records and the use of real-world data to improve dosing. Shownotes :00:00 Introduction02:58 User Demographics04:42 Integration with EHR10:20 Therapeutic Areas14:00 Bayesian Method16:20 Real-time Data20:20 Nerd Out on the Topic25:00 AUC-guided Dosing29:00 Implementation Process----- Links:* Sharmeen Roy LinkedIn (https://www.linkedin.com/in/sharmeenroy/)* DoseMe LinkedIn (https://www.linkedin.com/company/doseme-pty-ltd/ )* DoseMe website (https://doseme-rx.com/)*Harsh Thakkar LinkedIn ( https://www.linkedin.com/in/harshvthakkar/  )*Listen to this episode on the go!

Welcome to episode 047 of Life Sciences 360.In this video, We discuss the importance of using AI in decision making in the life sciences industry. Ben  highlight the need for evidence-based decision making and the challenges of finding relevant information in a sea of data. Ben introduce InVision, a platform that helps biotech and pharma companies stay informed about clinical trials and changes in the industry. Watch the video to learn how AI can assist in making informed decisions in the life sciences field.Chapters :00:00 - Introduction00:24 - AI in Decision-Making00:45 - Welcome and Guest Introduction01:00 - InThought Research and Infernesis02:00 - Challenges in Clinical Trials03:40 - InVision Technology Platform06:36 - AI Integration in InVision08:22 - Machine Learning and Natural Language Processing13:20 - Case Study: Clinical Trial Data Analysis17:56 - Privacy and Regulation in Healthcare19:34 - AI and Job Security24:21 -Practical Applications of AI26:16 - Spire Bioadvisors29:40 - Trends in Biotech and Drug Development32:58 - Future of AI in Healthcare37:28 - Ben's Personal Insights39:12 - Closing Thoughts----- Links:* Ben Weintraub LinkedIn (https://www.linkedin.com/in/ben-weintraub-0566389/)* inThought Research LinkedIn (https://www.linkedin.com/company/inthought-research/ )* inThought Research website (https://inthought.com/)*Harsh Thakkar LinkedIn ( https://www.linkedin.com/in/harshvthakkar/  )*Listen to this episode on the go! 

Welcome to episode 046 of Life Sciences 360.On this episode, Harsh discuss the intersection of luck and preparation in finding opportunities, particularly in the field of cell therapy. Harsh share insights from his conversation with Dr. Jason Bock, founder and CEO of CTMC, about the advancements and challenges in autologous cell therapies. We delve into topics such as manufacturing, strategy formation, and the impact of cell therapy on oncology. This episode provides valuable information for anyone interested in the field and invites viewers to explore the possibilities of this groundbreaking technology.Show notes:00:00 Introduction02:40 Autologous Cell Therapies04:40 Formation of CTMC08:40 Recognition and Impact11:48 Challenges in Cell Therapy Manufacturing15:00 Acquisition of a Facility17:20 Unexpected Growth21:49 Houston's Support for Multi-Center Trials27:52 Conceptualizing Virtual Manufacturing34:20 Maintaining Focus and Vision----- Links:* Jason Bock LinkedIn ( https://www.linkedin.com/in/jason-b-bock/ )* CTMC LinkedIn(https://www.linkedin.com/company/celltherapymanufacturingcenter/)*CTMC website (https://ctmc.com/)*Harsh Thakkar LinkedIn ( https://www.linkedin.com/in/harshvthakkar/)*Listen to this episode on the go! 

Welcome to episode 045 of Life Sciences 360. On this episode, Nagesh Nama and his team at XLM talk on why Gen.AI is essential in the software test world and share examples of its use in various industries, particularly in life sciences and manufacturing. They address the challenges faced by companies in adopting AI and provide solutions for integrating AI into existing systems. Harsh and his guests discuss how AI can improve productivity, enhance quality assurance processes, and enable proactive decision-making. The conversation emphasizes the importance of having an AI strategy and encourages SMBs to embrace AI to gain a competitive advantage. ----- Links:* Nagesh Nama LinkedIn * xLM LinkedIn *xLM website *Harsh Thakkar LinkedIn *Would you rather watch this episode? Click here for the YouTube episode.

Dr. Arnon Chait, CEO of Cleveland Diagnostics, discusses his transition from NASA to the healthcare innovation space and the development of cancer diagnostics.Dr. Chait emphasizes the importance of using diagnostic advancements to strike a balance between over-screening and under-treating, particularly in the workup of cancer after failed screenings.  He discusses the development of their innovative prostate cancer diagnostic test. In Episode 044 of Life Sciences 360, Harsh and Arnon also emphasize the importance of asking the right questions in scientific research and the need for simple and actionable diagnostic tools in healthcare. They advise individuals to stay curious and interested in order to be productive and successful.-----Links:*Arnon LinkedIn *Cleveland Diagnostics *Harsh Thakkar LinkedIn *Would you rather watch on YouTube, Click HERE

With the market estimated to reach $11.5 billion by 2028. Clean Rooms on Demand is providing flexible and cost-effective solutions for biotech and pharma companies. The benefits of using clean rooms on demand include avoiding the high capital outlay and ongoing operational expenses of building and maintaining their own facilities, as well as the flexibility to scale up or down as needed. Join me in Episode 43 of Life Sciences 360, with Sarah Stevens, the President of Azzur Labs and Azzur Cleanrooms on Demand, part of Azzur Group-----Links:*Sarah Stevens LinkedIn *Azzur Group *Harsh Thakkar LinkedIn *Would you rather watch? Click here. ----- Show Notes:(0:00) The Growing Cleanroom Technology Market(3:29) Benefits of Cleanrooms on Demand(6:41) A broader view of biotech lab solutions(9:02) Customer Case Studies and Segments(12:22) Expansion and Future Plans of Azzur Labs(14:29) Global Expansion and Strategic Vision(16:47) Sarah Stevens' Personal Career Journey (21:26) The Azzur Culture and Team DynamicsFor more, check out the podcast website - www.lifesciencespod.com

How can behavioral science optimize pharmaceutical practices? Episode 042: Will Hind, CEO of Alpharmaxim Healthcare Communications, discusses the challenges and opportunities in integrating behavioral science with pharma strategies. Find out how this can lead to better patient outcomes and more tailored healthcare solutions. -----Links: *Will Hind LinkedIn*Will Hind X*Alpharmaxim*Harsh Thakkar LinkedIn*Would you rather watch the episode? Click here!

Episode 041: J.D. Mowery, President and CEO of KBI Biopharma, discusses his career journey and the role of CDMOs in the biotech and pharma industry. He emphasizes the importance of relationships, risk-taking, and continuous learning in his career success. J.D. highlights the unique combination of expertise required to work in both biotech and CDMO companies. He explains the challenges faced by biotech and pharma companies that have led to the rise of CDMOs. Harsh asks J.D. to share the key factors to consider when selecting a CDMO. They introduce the concept of a next-generation CDMO, focusing on regulatory leadership, R&D and innovation, and risk sharing. -----Links:*J.D. Mowery LinkedIn*KBI Biopharma *Harsh Thakkar LinkedIn *Would you rather watch the episode? Click here! 

Are you interested in how the latest flow technology is transforming biopharmaceutical manufacturing? Join us for Episode 40 of the Life Sciences 360 podcast, where Harsh Thakkar (@harshvthakkar), CEO of Qualtivate sits down with Bethany Silva (@bethany-silva), Life Sciences Industry Manager at Endress+Hauser. They delve deep into the world of flow measurement, focusing on the cutting-edge single-use flow meters based on the Coriolis principle and how this technology is crucial for the development and production of biologics.

Toon Lambrechts, co-founder of MyCellHub, shares his journey in democratizing access to cell and gene therapy. He discusses the challenges in cell therapy manufacturing, including the high costs and complex logistics. MyCellHub aims to reduce manufacturing costs and automate processes to make cell therapies more affordable and accessible. Toon emphasizes the importance of networking and collaboration in building a successful team. He also discusses the future of the industry, including the use of natural language processing and automation. MyCellHub's ultimate goal is to scale up cell therapies and make them accessible to everyone.Episode 39: Harsh Thakkar (@harshvthakkar) interviews Toon Lambrechts (@toon-lambrechts).-----Links:*MyCellHub*Would you rather watch on YouTube?-----Show Notes:(0:00) Challenges in Cell Therapy(6:12) Cell Therapy Manufacturing Costs & Automation(12:48) Building a Data Management Platform(18:47) Entrepreneurship, Innovation, & Technology(24:35) Using AI in Cell & Gene TherapyFor more, check out the podcast website - www.lifesciencespod.com

Aaron Golub, a consultant and speaker, shares his story of overcoming adversity as a legally blind athlete and ex-NFL free agent. He discusses his journey from being a third-string high school athlete to becoming the first legally blind Division I athlete. Aaron also talks about his transition from sports to a career in finance and eventually to consulting with companies. He emphasizes the importance of qualities such as resilience, empathy, and effective communication in leadership. Aaron shares his perspective on coping with personal adversity and tailoring his advice for different audiences. He aims to be remembered as someone who gave his all to help others succeed.Episode 038: Harsh Thakkar (@harshvthakkar) interviews Aaron Golub (@aarongolub), Consultant Speaker, helping organizations implement leadership strategies and overcome adversity.-----Links:*Aaron's website *Aaron's email (aaron@aarongolub.com)-----Show Notes:(0:00) Overcoming adversity in sports and life.(4:06) Defeating the odds and inspiring others.(9:01) Leadership development and personal resilience.(14:44) Finding gratitude and success despite hardship.For more, check out the podcast website - www.lifesciencespod.com

He scaled his business from 0 to 20 million in under 3 years. Get inspired by the story of Scott Nelson's strategic brilliance and entrepreneurial triumph with Joovv and FastWave Medical, a groundbreaking MedTech startup reshaping the industry landscape. Learn about the strategic decisions, challenges overcome, and pivotal moments that defined Scott's path to success. Harsh and Scott also discuss the challenges and rewards of transitioning from working with large strategic companies to early-stage startups. They emphasize the importance of taking risks, learning from experiences, and being prepared for the ups and downs of entrepreneurship. You're watching Episode 037: Harsh Thakkar (@harshvthakkar) interviews Scott Nelson (@scottnelsonlive), Co-Founder, President, & CEO of FastWave Medical. -----Links: *Fast wave medical *Joovv *If you enjoy this type of content, or would like to watch this episode, subscribe and give us a like on YouTube !-----Show Notes:(0:00) Entrepreneurship, Med-Tech, and startup journey.(2:40) A new medical device for treating complex artery disease.(6:04) Transitioning from corporate to startup life. (9:38) Career advice and growth strategies for startups & entrepreneurs.(13:52) Learning from experience.(18:48) Decision-making, and consumer health trends.(21:10) Perfect is the enemy of good.For more, check out the podcast website - www.lifesciencespod.com

Weronika discusses the importance of integrating software with other systems for success and touches on various challenges such as data integration, user needs, and documentation practices. She highlights the evolving role of AI and software in healthcare, emphasizing patient-centered solutions and the importance of continuous learning in the Med-Tech industry. Harsh and Weronika focus on software as a medical device within the healthcare ecosystem. They cover choosing the right development partner, future trends, and advice for those entering the industry. Episode 036: Harsh Thakkar (@harshvthakkar) interviews Weronika Michaluk (@weronika-michaluk), the Principal Software as a Medical Device Lead at HTD Health.-----Links: *HTD Health*SaMD Series Article*Watch this episode on YouTube-----Show Notes:(0:00) Introduction to Weronika and HTD Health(1:49) Role and Projects at HTD Health(4:05) Early-stage Development and Medical Device Software(10:57) Patient Engagement and Software Design(12:13) Choosing the Right Development Partner(19:04) AI in Healthcare and Future Trends(20:15) Advice for Entering the Med-Tech Industry(24:46) Looking Forward to 2024 and BeyondFor more, check out the podcast website - www.lifesciencespod.com

Heather talks about the role of art in quality and documentation, challenges with document control methods, and her experience writing an article for Quality Magazine. She shares advice for entering the life sciences industry and the role of mentors in career development. Harsh and Heather also address the importance of mental health for leaders, the positive outcomes of supporting mental health, and creating programs for employee well-being. Episode 035: Harsh Thakkar (@harshvthakkar) interviews Heather Wilson (@heatherwilson2), the Associate Director of QMS and Document Control Administration at Xencor. -----Links:*MentalHealthyNewsletter*Quality Magazine Article *Would you rather watch the video episode? Subscribe to full-length videos on our YouTube Channel.-----Show Notes:(0:00) Document control and QMS in life sciences.(6:23) Writing an Article in Quality Magazine.(10:07) Mental health in the workplace and its impact on leaders.(16:57) Career advice for the life sciences industry.(24:16) Mentorship, networking and career development.(28:25) You should always ask for recommendations.For more, check out the podcast website - www.lifesciencespod.com

Episode 034: Harsh Thakkar (@harshvthakkar) interviews Kimberly Wallbank (@kimberlywallbank), the Principal Consultant at Quality Systems Services, LLC. Kimberly addresses the evolution of quality and regulatory practices, particularly the increased focus on risk assessment. She discusses the challenges companies face with compliance and the need for a cross-functional approach, as well as the importance of knowledge sharing, metrics, and making quality accessible to everyone.Harsh and Kimberly review misconceptions about quality management and stress the importance of understanding the role of quality assurance (QA) professionals in ensuring safety and efficacy. They agree that determining the true root cause of issues requires thorough investigation and consideration of various factors.-----Links:*Kimberly's LinkedIn *Quality Systems Services *Would you rather watch the video episode? Subscribe to full-length videos on our YouTube Channel.-----Show Notes:(0:00) Quality management misconceptions in life sciences. (2:45) Risk assessment and management in industry.(8:05) Sharing and Utilizing Risk Documents.(9:33) Determining True Root Cause. (14:27) Challenges with Compliance.(18:55) Knowledge Sharing and Metrics.For more, check out the podcast website - www.lifesciencespod.com